Say No To Trading
Public Markets Investor, Opportunistic Buying & Cost-Basis Management
Lumentum's valuation echoes JDS Uniphase, half of which became Lumentum, because both rest on distant buildout expectations that may not materialize. If Lumentum hits estimates two years out and earnings then plateau, the valuation would be insane; only later years justify it, and JDSU also had rational forward multiples in the out years. @KairosPraxis counters that Lumentum has good contract visibility for two years, unlike JDSU's $100B value on $1B of revenue. x.com x.com x.comÂ
Lumentum requires paying up heavily for a company that is not yet making money. Revenue grew 109% year over year, but it trades at about 25 times annualized sales, and it is growing less than memory makers at ten times their valuation. @ZeekTyt cites Lumentum's CEO expecting to supply only about 30% of requested laser demand as CPO and NPO ramp in 2027, with balance around 2029-30. x.com x.comÂ
Marvell risks paying a peak-scarcity price for Lumentum if optical supply catches up by 2028-30. The proposed ~$99B deal values Lumentum at roughly 20x guided annualized revenue and 58x estimated after-tax operating income, while Lumentum, Coherent and Chinese suppliers are adding laser capacity. The DSP-and-laser combination has strategic logic, but durable scarcity economics and Nvidia's response remain uncertain. x.comÂ
Lumentum's optics business is too valuable to sell for less than $2,000 a share, making a rumored Marvell takeover implausible. Lumentum is worth at least $2,000 a share now; a $120 billion purchase would consume about 60% of Marvell's roughly $200 billion market value, while a fair price would be closer to $160 billion in this view. x.com x.com x.comÂ
Applied Optoelectronics looks undervalued if its capacity converts into the modeled revenue ramp. From disclosed capacity, quarterly revenue could rise from $858M in Q1 2027 to $1.89B in Q4 and $2.14B in Q1 2028, against a $6.8B market cap. A $7.5B annualized exit rate in 2027 at 40% gross margins would make an unchanged valuation surprising. Lumentum's capacity agreements into 2030-31 suggest demand may last beyond 2027-28, but execution risk remains. x.comÂ
Marvell looks interesting at less than 30x calendar-2027 EPS against expected 60-70% annual EPS growth, but overpaying for Lumentum could drive its shares lower. Marvell could pay up to $110B, roughly a 30% premium; the stock-versus-debt mix is unclear, and Lumentum holders might own a third of the combined company. If the deal falls apart, Marvell could rise 10-12%. x.comÂ
Lumentum's 109% year-on-year growth and sold-out capacity through 2029 make selling its AI optics exposure questionable. Bloomberg reported Marvell is in advanced talks to buy it; the appeal depends on the price, especially when holders of an $80 billion Lumentum would become holders of a $320 billion-plus Marvell growing 37%. x.comÂ
Marvell's potential Lumentum acquisition may fail to increase per-share value because the added profits may not cover dilution and financing costs. A simplified calculation using reported market values implies roughly 38%-45% more shares, requiring about 45% more combined net profit to preserve EPS; debt would add interest and repayment pressure. If the price already reflects future growth, a control premium and possible customer concerns add risk. x.comÂ
The Lumentum merger makes Marvell's path toward a $1 trillion valuation look clearer if it executes well. Jensen Huang had called Marvell the next $1 trillion company. Lumentum's demand is sold for the next two to three years, though whether that gives Marvell an edge remains an open question. Marvell looks like a long-term opportunity, but the route to building a position is still unclear. x.comÂ
Scale-up co-packaged optics will likely end up larger than currently priced in, which supports Lumentum. AAOI has a high probability of outperforming Lumentum. x.comÂ
Owning Lumentum's laser fab could secure Marvell's FY28 supply and hedge its DSP franchise as optical links shift to CPO. The rumored deal's strategy makes sense, but short-term pain is likely: at a 30% premium, roughly $17.5B in new debt and the rest in stock, rough math puts EPS dilution near 15%. It turns accretive only if Lumentum outgrows Marvell at today's guided rates for five or six more quarters, which looks achievable while the laser shortage lasts. x.com x.com x.comÂ
